Glomerular Diseases Associated Primarily with Asymptomatic or Gross Hematuria

Sawsan, M. Alzahrani, I H, Furness, P N: Glomerular changes in microscopic haematuria, studied by quantitative immunoelectron microscopy and in situ zymography. Nephol Dial Transplant 17:1586–1593, 2002.Google Scholar

Berger, J, Hinglas, N: Les depots intercapillaires IgA–IgG. J Urol Nephrol (Paris) 74:694–95, 1968.Google Scholar

D’Amico, G: Natural history of idiopathic IgA nephropathy: Role of clinical and histological prognostic factors. Am J Kidney Dis 36:227–237, 2000.Google Scholar

Lu, J C, Zhang, H, Zhou, Y, et al.: Natural history and predictive factors of prognosis: A long term follow up of 204 cases in China. Nephrology (Carlton) 13:242–246, 2008..Google Scholar

The United States Renal Data System Annual Data Report 2015. www.usrds.org.Google Scholar

Sugiyama, H, Yokoyama, H, Sato, H, et al.: Committee for Standardization of Renal Pathological Diagnosis; Committee for Kidney Disease Registry; Japanese Society of Nephrology: Japan Renal Biopsy Registry and Japan Kidney Disease Registry: Committee Report for 2009 and 2010. Clin Exp Nephrol 17:155–173, 2013.Google Scholar

Galla, J: IgA nephropathy. Kidney Int 47:377–387, 1995.Google Scholar

Hoy, W E, Samuel, T,Mott, S A, et al.: Renal biopsy findings among Indigenous Australians: A nationwide review. Kidney Int 82:1321–1331, 2012.Google Scholar

D’Amico, G: The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med 64:709–727, 2001.Google Scholar

Sinniah, R: Occurrence of mesangial IgA and IgM deposits in a control necropsy population. J Clin Pathol 36:276–279, 1983.Google Scholar

Galla, J H, Kohaut, E C, Alexander, R, et al.: Racial differencein the prevalence of IgA-associated nephropathies. Lancet 2:522, 1984.CrossRef Google Scholar

Jennette, J C, Wall, S D, Wilkman, A S: Low incidence of IgA nephropathy in blacks. Kidney Int 28:944–950, 1985.Google Scholar

McQuarrie, E P, Mackinnon, B, McNeice, V, Fox, J G, Geddes, C C: The incidence of biopsy-proven IgA nephropathy is associated with multiple socioeconomic deprivation. Kidney Int 85:198–203, 2014.Google Scholar

Wyatt, R J, Julian, B A: IgA nephropathy. N Engl J Med 368:2402–14, 2013.Google Scholar

Wyatt, R J, Julian, B A, Baehler, R W, et al.: Epidemiology of IgA nephropathy in central and eastern Kentucky for the period 1975 through 1994. J Am Soc Nephrol 9:853–858, 1998.Google Scholar

Wyatt, R J, Kritchevsky, S B, Woodford, S Y, et al.: IgA nephropathy: Long-term prognosis for pediatric patients. J Pediatr 127:913–919, 1995.Google Scholar

Philibert, D, Cattran, D, Cook, T: Clinicopathologic correlation in IgA nephropathy. Semin Nephrol 28:10–17, 2008.CrossRef Google Scholar PubMed

Herlitz, L C, Bomback, A S, Stokes, M B, et al.: IgA nephropathy with minimal change disease. Clin J Am Soc Nephrol 9:1033–1039, 2014.CrossRef Google Scholar PubMed

Yang, Y-Z, Shi, S-F,Chen, Y-Q, et al.: Clinical features of IgA nephropathy with serum ANCA-positivity: A retrospective case–control study. Clin Kidney J 8:482–488, 2015.CrossRef Google Scholar PubMed

Emancipator, S N: IgA nephropathy and Henoch–Scholein syndrome. In Jennette, J. C., Olson, J. L., Schwartz, M. M., and Silva, F. G., eds., Heptinstall’s Pathology of the Kidney, 5th ed., vol. 1 (Philadelphia: Lippincott-Raven, 1998), pp. 479–539.Google Scholar

Hogg, R J, Silva, F G, Wyatt, R J, et al.: Prognostic indicators in children with IgA nephropathy – Report of the Southwest Pediatric Nephrology Study Group. Pediatr Nephrol 8:15–20, 1994.Google Scholar

Ibels, L S, Gyory, A Z: IgA nephropathy: Analysis of the natural history, important factors in the progression of renal disease, and a review of the literature. Medicine 73:79–102, 1994.Google Scholar

Tang, Z, Wu, Y, Wang, Q W, et al.: Idiopathic IgA nephropathy with diffuse crescent formation. Am J Nephrol 22:480–486, 2002.Google Scholar

Tumlin, J A, Hennigar, R A: Clinical presentation, natural history, and treatment of crescentic proliferative IgA nephropathy. Semin Nephrol 24:256–268, 2004.CrossRef Google Scholar PubMed

D’Amico, G, Napodano, P, Ferrario, F, Rastaldi, M P, Arrigo, G: Idiopathic IgA nephropathy with segmental necrotizing lesions of the capillary wall. Kidney Int 59:682–692, 2001.Google Scholar

Haas, M, Jafri, J, Bartosh, S M, et al.: ANCA-associated crescentic glomerulonephritis with mesangial IgA deposits. Am J Kidney Dis 36:709–718, 2000.Google Scholar

Lee, S M, Rao, V M, Franklin, W A, et al.: IgA nephropathy: Morphologic predictors of progressive renal disease. Hum Pathol 13:314–322, 1982.CrossRef Google Scholar PubMed

Meadow, S R, Glasgow, E F, White, R H, et al.: Schonlein–Henoch nephritis. Quart J Med 41:241–258, 1972.Google Scholar

Haas, M: Histological subclassification of IgA nephropathy: A clinicopathologic study of 244 cases. Am J Kidney Dis 29:829–842, 1997.Google Scholar

Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Cattran, D C, Coppo, R, et al.: The Oxford classification of IgA nephropathy: Rationale, clinicopathological correlations, and classification. Kidney Int 76:534–545, 2009.Google Scholar

Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Roberts, I S, Cook, H T, et al.: The Oxford classification of IgA nephropathy: Pathology definitions, correlations, and reproducibility. Kidney Int 76:546–556, 2009.Google Scholar

Kawamura, T, Joh, K, Okonogi, H, et al.: Study Group Special IgA Nephropathy: A histologic classification of IgA nephropathy for predicting long-term prognosis: Emphasis on end-stage renal disease. J Nephrol 26:350–357, 2013.Google Scholar

Zeng, C H, Le, W, Ni, Z, et al.: A multicenter application and evaluation of the Oxford Classification of IgA Nephropathy in adult Chinese patients. Am J Kidney Dis 60:812–820, 2012.Google Scholar

Le, W, Zeng, C H, Liu, Z, et al.: Validation of the Oxford Classification of IgA nephropathy for pediatric patients from China. BMC Nephrol 13:158, 2012.Google Scholar

Katafuchi, R, Ninomiya, T, Nagata, M, Mitsuiki, K, Hirakata, H: Validation study of oxford classification of IgA nephropathy: The significance of extracapillary proliferation. Clin J Am Soc Nephrol 6:2806–2813, 2011.Google Scholar

Tumlin, J A, Lohavichan, V, Hennigar, R: Crescentic proliferative IgA nephropathy: Clinical and histologic response to methyl prednisolone and intravenous cyclophosphamide. Nephrol Dial Transplant 18:1321–1392, 2003.Google Scholar

Karoui, K E, Hill, G S, Karras, K, et al.: A clinicopathologic study of thrombotic microangiopathy in IgA nephropathy. J Am Soc Nephrol 23:137–148, 2012.Google Scholar

Gu, X, Herrera, G A: The value of electron microscopy in the diagnosis of IgA nephropathy. Ultrastruct Pathol 26:203–210, 2003.Google Scholar

Lee, H S, Choi, Y, Lee, J S, Yu, B H, Koh, H I: Ultrastructural changes in IgA nephropathy in relation to histologic and clinical data. Kidney Int 35:880–886, 1989.Google Scholar

Morita, M, Sakaguchi, H: A quantitative study of glomerular basement membrane changes in IgA nephropathy. J Pathol 154:7–18, 1988.Google Scholar

Vogler, C, Eliason, S C, Wood, E G: Glomerular membranopathy in children with IgA nephropathy and Henoch Schonlein purpura. Pediatr Dev Pathol 2:227–235, 1999.Google Scholar

Norby, S M, Cosio, F G: Thin basement membrane nephropathy associated with other glomerular diseases. Semin Nephrol 25:176–179, 2005.Google Scholar

Westhoff, T H, Waldherr, R, Loddenkemper, C, et al.: Mesangial IgA deposition in minimal change nephrotic syndrome: Coincidence of different entities or variant of minimal change disease? Clin Nephrol 65:203–207, 2006.Google Scholar

Nasr, S H, Markowitz, G S, Whelan, J D, et al.: IgA-dominant acute poststaphylococcal glomerulonephritis complicating diabetic nephropathy. Hum Pathol 34:1235–1241, 2003.Google Scholar

Koyama, A, Sharmin, S, Sakurai, H, Shimizu, Y, et al:. Staphylococcus aureus cell envelope antigen is a new candidate for the induction of IgA nephropathy. Kidney Int 66:121–132, 2004.CrossRef Google Scholar PubMed

Satoskar, A A, Nadasdy, G, Plaza, J A, et al.: Staphylococcus infection-associated glomerulonephritis mimicking IgA nephropathy. Clin J Am Soc Nephrol 1:1179–1186, 2006.Google Scholar

Newell, G: Cirrhotic glomerulonephritis: Incidence, morphology, clinical features and pathogenesis. Am J Kid Dis 9:183–190, 1987.Google Scholar

Haas, M: IgA nephropathy and IgA vasculitis (Henoch–Scholein purpura) nephritis. In Jennette, J. C., Olson, J. L., Silva, F. G., D’Agati, V. D. eds., Heptinstall’s Pathology of the Kidney, 7th ed., vol. 1 (Philadelphia: Wolters Kluwer, 2015), pp. 463–523.Google Scholar

Pouria, S, Barratt, J: Secondary IgA nephropathy. Semin Nephrol 28:27–37, 2008.Google Scholar

Smerud, H K, Fellström, B, Hällgren, R, et al.: Gluten sensitivity in patients with IgA nephropathy. Nephrol Dial Transplant 24:2476–2248, 2009.Google Scholar

Gerntholtz, T E, Goetsch, S J W, Katz, I: HIV-related nephropathy: A South African perspective. Kidney Int 69:1885–1891, 2006.Google Scholar

Beaufils, H, Jouanneau, C, Katlama, C, Sazdovitch, V, Hauw, J J: HIV-associated IgA nephropathy – A post-mortem study. Nephrol Dial Transplant 10:35–38, 1995.Google Scholar PubMed

Woof, J M, Russell, M W: Structure and function relationship in IgA. Mucosal Immunol 4:590–597, 2011.Google Scholar

Smith, A C, de Wolff, J F, Molyneux, K, Feehally, J, Barratt, J: O-Glycosylation of serum IgD in IgA nephropathy. J Am Soc Nephrol 17:1192–1199, 2006.Google Scholar

Barratt, J, Smith, A C, Feehally, J: The pathogenic role of IgA1 O-linked glycosylation in the pathogenesis of IgA nephropathy. Nephrology (Carlton) 12:275–284, 2007.Google Scholar

Tomana, M, Matousovic, K, Julian, B A, et al.: Galactose-deficient IgA1 in sera of IgA nephropathy patients is present in complexes with IgG. Kidney Int 52:509–516, 1997.Google Scholar

Allen, A C, Bailey, E M, Brenchley, P E, et al.: Mesangial IgA1 in IgA nephropathy exhibits aberrant O-glycosylation: Observations in three patients. Kidney Int 60:969–973, 2001.Google Scholar

Suzuki, H, Kiryluk, K, Novak, J, et al.: The pathophysiology of IgA nephropathy. J Am Soc Nephrol 22:1795–1803, 2011.Google Scholar

Kiryluk, K, Novak, J, Gharavi, A G: Pathogenesis of immunoglobulin A nephropathy: Recent insight from genetic studies. Annu Rev Med 64:339–356, 2013.Google Scholar

Mestecky, J, Raska, M, Julian, B A, et al.: IgA nephropathy: Molecular mechanisms of the disease. Annu Rev Pathol 8:217–240, 2013.CrossRef Google Scholar PubMed

Magistroni, R, D’Agati, V D, Appel, G B, Kirluk, K: New developments in the genetics, pathogenesis, and therapy of IgA nephropathy. Kidney Int 8:974–989, 2015.Google Scholar

Novak, J, Renfrow, M B, Gharavi, A G, Julian, B A: Pathogenesis of immunoglobulin A nephropathy. Curr Opin Nephrol Hypertens 22:287–294, 2013.Google Scholar

Boyd, J K, Cheung, C K, Molyneux, K, Feehally, J, Barratt, J: An update on the pathogenesis and treatment of IgA nephropathy. Kidney Int 81:833–843, 2012.Google Scholar

Barratt, J, Eitner, F, Feehally, J, Floege, J: Immune complex formation in IgA nephropathy: A case of the ‘right’ antibodies in the ‘wrong’ place at the ‘wrong’ time? Nephrol Dial Transplant 24:3620–3623, 2009.Google Scholar

Serino, G, Sallustio, F, Cox, S N, Pesce, F, Schena, F P: Abnormal miR-148b expression promotes aberrant glycosylation of IgA1 in IgA nephropathy. J Am Soc Nephrol 23:814–824, 2012.Google Scholar

Suzuki, H, Fan, R, Zhang, Z, et al. Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J Clin Invest 119:1668–1677, 2009.Google Scholar

Novak, J, Julian, B A, Mestecky, J, Renfrow, M B: Glycosylation of IgA1 and pathogenesis of IgA nephropathy. Semin Immunopathol 34:365–382, 2012.Google Scholar

Vuong, M T, Hahn-Zoric, M, Lundberg, S, et al.: Association of soluble CD89 levels with disease progression but not susceptibility in IgA nephropathy. Kidney Int 78:1281–1287, 2010.Google Scholar

Moura, I C, Centelles, M N, Arcos-Fajardo, M, et al.: Identification of the transferrin receptor as a novel immunoglobulin (Ig)A1 receptor and its enhanced expression on mesangial cells in IgA nephropathy. J Exp Med 194:417–425, 2001.Google Scholar

Kaneko, Y, Otsuka, T, Tsuchida, Y, Gejyo, F, Narita, I: Integrin α1/β1 and α2/β1 as a receptor for IgA1 in human glomerular mesangial cells in IgA nephropathy. Int Immunol 24:219–232, 2012.Google Scholar

Amore, A, Conti, G, Cirina, P, et al.: Aberrantly glycosylated IgA molecules downregulate the synthesis and secretion of vascular endothelial growth factor in human mesangial cells. Am J Kidney Dis 36:1242–1252, 2000.Google Scholar

Lai, K N: Pathogenesis of IgA nephropathy. Nat Rev Nephrol 8:275–283, 2012.Google Scholar

Lai, K N, Leung, J C, Chan, L Y, et al.: Activation of podocytes by mesangial derived TNF-alpha: Glomerulo-podocytic communication in IgA nephropathy. Am J Physiol Renal Physiol 294:F945–F955, 2008.Google Scholar

Daha, M R, van Kooten, C: Deposition of IgA in primary IgA nephropathy: It takes at least four to tango. Nephrol Dial Transplant 28:794–797, 2013.Google Scholar

BenMkaddem, S, Rossato, E, Heming, N, Monteiro, R C: Anti-inflammatory role of the IgA Fc receptor (CD89): From autoimmunity to therapeutic perspectives. Autoimmun Rev 12:666–669, 2013.Google Scholar

Nadalutti, C A, Korponay-Szabo, I R, Kaukinen, K, et al.: Celiac disease patient IgA antibodies induce endothelial adhesion and cell polarization defects via extracellular transglutaminase. Cell Mol Life Sci 71:1315–1326, 2014.Google Scholar

Tissandié, E, Morelle, W, Berthelot, L, et al.: Both IgA nephropathy and alcoholic cirrhosis feature abnormally glycosylated IgA1 and soluble CD89–IgA and IgG–IgA complexes: Common mechanisms for distinct diseases. Kidney Int 80:1352–1363, 2011.Google Scholar

Novak, J, Julian, B A: Sugars and alcohol: IgA-associated renal diseases in alcoholic cirrhosis. Kidney Int 80:1252–1254, 2011.Google Scholar

Zhu, L, Zhang, Q, Shi, S, et al.: Synergistic effect of mesangial cell-induced CXCL1 and TGF-b1 in promoting podocyte loss in IgA nephropathy. PLoS ONE 8:e73425, 2013.Google Scholar

Cox, S N, Sallustio, F, Serino, G, et al.: Activated innate immunity and the involvement of CX3CR1-fractalkine in promoting hematuria in patients with IgA nephropathy. Kidney Int 82:548–560, 2012.CrossRef Google Scholar PubMed

Eitner, F, Floege, J: In search of a better understanding of IgA nephropathy associated hematuria. Kidney Int 82:513–515, 2012.Google Scholar

Carlsson, M C, Bakoush, O, Tengroth, L, et al.: Galectin-8 in IgA nephritis: Decreased binding of IgA by galectin-8 affinity chromatography and associated increased binding in non-IgA serum glycoproteins. J Clin Immunol 32:246–255, 2012.Google Scholar

Tamouza, H, Chemouny, JM, Raskova Kafkova, L, et al.: The IgA1 immune complex-mediated activation of the MAPK/ERK kinase pathway in mesangial cells is associated with glomerular damage in IgA nephropathy. Kidney Int 82:1284–1296, 2012.Google Scholar

Jin, J, Xiao, Y, Chang, J H, et al.: The kinase TBK1 controls IgA class switching by negatively regulating noncanonical NF-kB signaling. Nat Immunol 13:1101–1109, 2012.Google Scholar

Nagai, K, Miyoshi, M, Kake, T, et al.: Dual involvement of growth arrest-specific gene 6 in the early phase of human IgA nephropathy. PLoS ONE 8:e66759, 2013.Google Scholar

Wang, Y Y, Zhang, L, Zhao, P W, et al.: Functional implications of regulatory B cells in human IgA nephropathy. Scand J Immunol 79:51–60, 2014.CrossRef Google Scholar PubMed

Takechi, H, Oda, T, Hotta, O, et al.: Clinical and immunological implications of increase in CD2081 dendritic cells in tonsils of patients with immunoglobulin A nephropathy. Nephrol Dial Transplant 28:3004–3013, 2013.Google Scholar

Wada, T, Nangaku, M: Novel roles of complement in renal diseases and their therapeutic consequences. Kidney Int 84:441–450, 2013.Google Scholar

Scolari, F, Amoroso, A, Savoldi, S, et al. Familial clustering of IgA nephropathy: Further evidence in an Italian population. Am J Kid Dis 33:857–865, 1999.Google Scholar

Moldoveanu, Z, Wyatt, R J, Lee, J Y, et al.: Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels. Kidney Int 71:1148–1154, 2007.Google Scholar

Gharavi, A G, Moldoveanu, Z, Wyatt, R J, et al.: Aberrant IgA1 glycosylation is inherited in familial and sporadic IgA nephropathy. J Am Soc Nephrol 19:1008–1014, 2008.Google Scholar

Lin, X, Ding, J, Zhu, L, et al.: Aberrant galactosylation of IgA1 is involved in the genetic susceptibility of Chinese patients with IgA nephropathy. Nephrol Dial Transplant 24:3372–3375, 2009.Google Scholar

Feehally, J, Farrall, M, Boland, A, et al.: HLA has strongest association with IgA nephropathy in genome-wide analysis. J Am Soc Nephrol 21:1791–1797, 2010Google Scholar

Gharavi, A G, Kiryluk, K, Choi, M, et al.: Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet 43:321–327, 2011.Google Scholar

Kiryluk, K, Li, Y, Sanna-Cherchi, S, et al.: Geographic differences in genetic susceptibility to IgA nephropathy: GWAS replication study and geospatial risk analysis. PLoS Genet 8:e1002765, 2012.Google Scholar

Lin, X, Ding, J, Zhu, L, et al.: Aberrant galactosylation of IgA1 is involved in the genetic susceptibility of Chinese patients with IgA nephropathy. Nephrol Dial Transplant 24:3372–3375, 2009.Google Scholar

Li, G S, Nie, G J, Zhang, H, et al.: Do the mutations of C1GALT1C1 gene play important roles in the genetic susceptibility to Chinese IgA nephropathy? BMC Med Genet 10:101, 2009.Google Scholar

Pirulli, D, Crovella, S, Ulivi, S, et al.: Genetic variant of C1GalT1 contributes to the susceptibility to IgA nephropathy. J Nephrol 22:152–159, 2009.Google Scholar

Buck, K S, Smith, A C, Molyneux, K, et al.: B-cell O-galactosyltransferase activity, and expression of O-glycosylation genes in bone marrow in IgA nephropathy. Kidney Int 73:1128–1136, 2008.Google Scholar

Ding, J X, Xu, L X, Zhu, L, et al.: Activity of alpha2,6-sialyltransferase and its gene expression in peripheral B lymphocytes in patients with IgA nephropathy. Scand J Immunol 69:174–180, 2009.Google Scholar

Zhu, L, Tang, W, Li, G, et al.: Interaction between variants of two glycosyltransferase genes in IgA nephropathy. Kidney Int 76:190–198, 2009.Google Scholar

Li, R, Xue, C, Li, C, et al.: TRAC variants associate with IgA nephropathy. J Am Soc Nephrol 20:1359–1367, 2009.Google Scholar

Woo, K T, Lau, Y K, Wong, K S, Zhao, Y, Chan, C M: Parallel genotyping of 10,204 single nucleotide polymorphisms to screen for susceptible genes for IgA nephropathy. Ann Acad Med Singapore 38:894–899, 2009.Google Scholar

Yamamoto, R, Nagasawa, Y, Shoji, T, et al.: A candidate gene approach to genetic prognostic factors of IgA nephropathy: A result of Polymorphism REsearch to Distinguish genetic factors Contributing To progression of IgA Nephropathy (PREDICT-IgAN). Nephrol Dial Transplant 24:3686–3694, 2009.Google Scholar

Chin, H J, Cho, H J, Lee, T W, et al.: The heme oxygenase-1 genotype is a risk factor to renal impairment of IgA nephropathy at diagnosis, which is a strong predictor of mortality. J Korean Med Sci 24(Suppl):S30–S37, 2009.Google Scholar

Ai, Z, Li, M, Liu, W, et al: Low α-defensin gene copy number increases the risk for IgA nephropathy and renal dysfunction. Sci Transl Med 8(345):345ra88, 2016.Google Scholar

Lim, C S, Kim, S M, Oh, Y K, et al.: Megsin 2093T–2180C haplotype at the 3ʹ untranslated region is associated with poor renal survival in Korean IgA nephropathy patients. Clin Nephrol 70:101–109, 2008.Google Scholar

Vuong, M T, Lundberg, S, Gunnarsson, I, et al.: Genetic variation in the transforming growth factor beta 1 gene is associated with susceptibility to IgA nephropathy. Nephrol Dial Transplant 24:3061–3067, 2009.Google Scholar

Kim, S M, Chin, H J, Oh, Y K, et al.: Blood pressure-related genes and the progression of IgA nephropathy. Nephron Clin Pract 113:c301–c308, 2009.Google Scholar

Cao, H X, Li, M, Nie, J, et al.: Human leukocyte antigen DRB1 alleles predict risk and disease progression of immunoglobulin A nephropathy in Han Chinese. Am J Nephrol 28:684–691, 2008.Google Scholar

Hahn, W H, Cho, B S, Kim, S D, Kim, S K, Kang, S: Interleukin-1 cluster gene polymorphisms in childhood IgA nephropathy. Pediatr Nephrol 24:1329–1336, 2009.Google Scholar

Bertinetto, F E, Calafell, F, Roggero, S, et al.: European IgA Nephropathy Consortium: Search for genetic association between IgA nephropathy and candidate genes selected by function or by gene mapping at loci IGAN2 and IGAN3. Nephrol Dial Transplant 27:2328–2337, 2012.Google Scholar

Zhou, X J, Cheng, F J, Qi, Y Y, et al.: FCGR2B and FCRLB gene polymorphisms associated with IgA nephropathy. PLoS ONE 8:e61208, 2013.Google Scholar

Yamamoto, R, Nagasawa, Y, Shoji, T, et al.: A candidate gene approach to genetic contributors to the development of IgA nephropathy. Nephrol Dial Transplant 27:1020–1030, 2012.Google Scholar

Yang, C, Jie, W, Yanlong, Y, et al.: Genome-wide association study identifies TNFSF13 as a susceptibility gene for IgA in a South Chinese population in smokers. Immunogenetics 64:747–753, 2012.Google Scholar

Yu, X Q, Li, M, Zhang, H, et al.: A genome-wide association study in Han Chinese identifies multiple susceptibility loci for IgA nephropathy. Nat Genet 44:178–182, 2012.Google Scholar

Lasseur, C, Allen, A C, Deminiere, C, et al.: Henoch–Schonlein purpura with immunoglobulin A nephropathy and abnormalities of immunoglobulin A in a Wiskott–Aldrich syndrome carrier. Am J Kidney Dis 29:285–287, 1997.Google Scholar

Zickerman, A M, Allen, A C, Talwar, V, et al.: IgA myeloma presenting as Henoch–Schonlein purpura with nephritis. Am J Kidney Dis 36:E19, 2000.Google Scholar

Roccatello, D, Picciotto, G, Torchio, M, et al.: Removal systems of immunoglobulin A and immunoglobulin A containing complexes in IgA nephropathy and cirrhosis patients. The role of asialoglycoprotein receptors. Lab Invest 69:714–723, 1993.Google Scholar

Pouria, S, Feehally, J: Glomerular IgA deposition in liver disease. Nephrol Dial Transplant 14:2279–2282, 1999.Google Scholar

Feehally, J, Beattie, T J, Brenchley, P E, et al.: Response of circulating immune complexes to food challenge in relapsing IgA nephropathy. Pediatr Nephrol 1:581–586, 1987.Google Scholar

Papista, C, Lechner, S, Mkaddem, S B, et al.: Gluten exacerbates IgA nephropathy in humanized mice through gliadin–CD89 interaction. Kidney Int 88:276–285, 2015.Google Scholar

Kidney Disease Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group: KDIGO clinical practice guideline for glomerulonephritis. Kidney Int 2(Suppl):139–274, 2012.Google Scholar

Barbour, S J, Reich, H N: Risk stratification of patients with IgA nephropathy. Am J Kidney Dis 59:865–873, 2012.Google Scholar

Chou, Y H, Lien, Y C, Hu, F C, et al.: Clinical outcomes and predictors for ESRD and mortality in primary GN. Clin J Am Soc Nephrol 7:1401–1408, 2012.Google Scholar

Le, W, Liang, S, Hu, Y, et al.: Long-term renal survival and related risk factors in patients with IgA nephropathy: Results from a cohort of 1155 cases in a Chinese adult population. Nephrol Dial Transplant 27:1479–1485, 2012.Google Scholar

Reich, H N, Troyanov, S, Scholey, J W, Cattran, D C: Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol 18:3177–3183, 2007.Google Scholar

Barbour, S J, Cattran, D C, Kim, S J, et al. Individuals of Pacific Asian origin with IgA nephropathy have an increased risk of progression to end-stage renal disease. Kidney Int 84:1017–1024, 2013.Google Scholar

Duan, Z Y, Cai, G Y, Chen, Y Z, et al.: Aging promotes progression of IgA nephropathy: A systematic review and meta-analysis. Am J Nephrol 38:241–252, 2013.Google Scholar

Berthoux, F, Mariat, C, Maillard, N: Overweight/obesity revisited as a predictive risk factor in primary IgA nephropathy. Nephrol Dial Transplant 28(Suppl 4):iv160–iv166, 2013.Google Scholar

Lv, J, Shi, S, Xu, D, et al.: Evaluation of the Oxford Classification of IgA nephropathy: A systematic review and meta-analysis. Am J Kidney Dis 62:891–899, 2013.Google Scholar

Liu, L J, Li, G T, Zhou, Y, Lu, C, Zhang, H: Clinicopathologic features and outcomes in endocapillary proliferative IgA nephropathy. Nephron Clin Pract 115:c161–c167, 2010.Google Scholar

Walsh, M, Sar, A, Lee, D, et al.: Histopathologic features aid in predicting risk for progression of IgA nephropathy. Clin J Am Soc Nephrol 5:425–430, 2010.Google Scholar

Lu, J, Yang, Y, Zhang, H, et al.: Prediction of outcomes in crescentic IgA nephropathy in a multicenter cohort study. J Am Soc Nephrol 24:2118–2125, 2013.Google Scholar

Shimizu, A, Takei, T, Moriyama, T, et al.: Clinical and pathological studies of IgA nephropathy presenting as a rapidly progressive form of glomerulonephritis. Intern Med 52:2489–2494, 2013.Google Scholar

Gutiérrez, E, Zamora, I, Ballarín, J A, et al.: Long-term outcomes of IgA nephropathy presenting with minimal or no proteinuria. J Am Soc Nephrol 23:1753–1760, 2012.Google Scholar

Xu, L, Yang, H C, Hao, C M, et al.: Podocyte number predicts progression of proteinuria in IgA nephropathy. Mod Pathol 23:1241–1250, 2010.Google Scholar

Hill, G S, Karoui, K E, Karras, A, et al.: Focal segmental glomerulosclerosis plays a major role in the progression of IgA nephropathy. I. Immunohistochemical studies. Kidney Int 79:635–642, 2011.Google Scholar

El Karoui, K, Hill, G S, Karras, A, et al.: Focal segmental glomerulosclerosis plays a major role in the progression of IgA nephropathy. II. Light microscopic and clinical studies. Kidney Int 79:643–654, 2011.Google Scholar

Tsuboi, N, Kawamura, T, Koike, K, et al: Glomerular density in renal biopsy specimens predicts the long-term prognosis of IgA nephropathy. Clin J Am Soc Nephrol 5:39–44, 2010.Google Scholar

Lee, H J, Choi, S Y, Jeong, K H, et al.: Association of C1q deposition with renal outcomes in IgA nephropathy. Clin Nephrol 80:98–104, 2013.Google Scholar

Kim, S J, Koo, H M, Lim, B J, et al.: Decreased circulating C3 levels and mesangial C3 deposition predict renal outcome in patients with IgA nephropathy. PLoS ONE 7:e40495, 2012.Google Scholar

Wada, Y, Ogata, H, Takeshige, Y, et al.: Clinical significance of IgG deposition in the glomerular mesangial area in patients with IgA nephropathy. Clin Exp Nephrol 17:73–82, 2013.Google Scholar

Liu, L L, Liu, N, Chen, Y, et al.: Glomerular mannose-binding lectin deposition is a useful prognostic predictor in immunoglobulin A nephropathy. Clin Exp Immunol 174:152–160, 2013.Google Scholar

Tanaka, S, Ninomiya, T, Katafuchi, R, et al.: Development and validation of a prediction rule using the Oxford classification in IgA nephropathy. Clin J Am Soc Nephrol 8:2082–2090, 2013.Google Scholar

Xie, J, Kiryluk, K, Wang, W, et al.: Predicting progression of IgA nephropathy: New clinical progression risk score. PLoS ONE 7:e38904, 2012.Google Scholar

Berthoux, F, Mohey, H, Laurent, B, et al.: Predicting the risk for dialysis or death in IgA nephropathy. J Am Soc Nephrol 22:752–761, 2011.Google Scholar

Fujimi-Hayashida, A, Ueda, S, Yamagishi, S, et al.: Association of asymmetric dimethylarginine with severity of kidney injury and decline in kidney function in IgA nephropathy. Am J Nephrol 33:1–6, 2011.Google Scholar

Peters, H P, Waanders, F, Meijer, E, et al.: High urinary excretion of kidney injury molecule-1 is an independent predictor of end-stage renal disease in patients with IgA nephropathy. Nephrol Dial Transplant 26:3581–3588, 2011.Google Scholar

Xu, P C, Zhang, J J, Chen, M, et al.: Urinary kidney injury molecule-1 in patients with IgA nephropathy is closely associated with disease severity. Nephrol Dial Transplant 26:3229–3236, 2011.Google Scholar

Meng, H, Zhang, L, E, X, et al.: Application of Oxford classification, and overexpression of transforming growth factor-b1 and immunoglobulins in immunoglobulin A nephropathy: Correlation with World Health Organization classification of immunoglobulin A nephropathy in a Chinese patient cohort. Transl Res 163:8–18, 2014.Google Scholar

Gutiérrez, E, Egido, J, Rubio-Navarro, A, et al.: Oxidative stress, macrophage infiltration and CD163 expression are determinants of long-term renal outcome in macrohematuria-induced acute kidney injury of IgA nephropathy. Nephron Clin Pract 121:c42–c53, 2012.Google Scholar

Lin, F J, Jiang, G R, Shan, J P, et al.: Imbalance of regulatory T cells to Th17 cells in IgA nephropathy. Scand J Clin Lab Invest 72:221–229, 2012.Google Scholar

Berthoux, F, Suzuki, H, Thibaudin, L, et al.: Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy. J Am Soc Nephrol 23:1579–1587, 2012.Google Scholar

Beck, L, Bomback, A S, Choi, M J, et al.: KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis. Am J Kidney Dis 62:403–441, 2013.Google Scholar

Li, P K, Kwan, B C, Chow, K M, Leung, C B, Szeto, C C: Treatment of early immunoglobulin A nephropathy by angiotensin-converting enzyme inhibitor. Am J Med 126:162–168, 2013.Google Scholar

Praga, M, Gutierrez, E, Gonzalez, E, Morales, E, Hernandez, E: Treatment of IgA nephropathy with ACE inhibitors: A randomized and controlled trial. J Am Soc Nephrol 14:1578–1583, 2003.Google Scholar

Coppo, R, Peruzzi, L, Amore, A, et al.: IgACE: A placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. J Am Soc Nephrol 18:1880–1888, 2007.Google Scholar

Cheng, J, Zhang, X, Tian, J, Li, Q, Chen, J: Combination therapy an ACE inhibitor and an angiotensin receptor blocker for IgA nephropathy: A meta-analysis. Int J Clin Pract 66:917–923, 2012.Google Scholar

Szeto, C C, Kwan, B C, Chow, K M, Leung, C B, Li, P K: The safety and short-term efficacy of aliskiren in the treatment of immunoglobulin a nephropathy– A randomized cross-over study. PLoS ONE 8:e62736, 2013.Google Scholar

Liu, L L, Wang, L N: ω-3 fatty acids therapy for IgA nephropathy: A meta-analysis of randomized controlled trials. Clin Nephrol 77:119–125, 2012.Google Scholar

Chou, H H, Chiou, Y Y, Hung, P H, Chiang, P C, Wang, S T: Omega-3 fatty acids ameliorate proteinuria but not renal function in IgA nephropathy: A meta-analysis of randomized controlled trials. Nephron Clin Pract 121:c30–c35, 2012.Google Scholar

Lv, J, Xu, D, Perkovic, V, et al.: Corticosteroid therapy in IgA nephropathy. J Am Soc Nephrol 23:1108–1116, 2012.Google Scholar

Lv, J, Zhang, H, Chen, Y, et al.: Combination therapy of prednisone and ACE inhibitor versus ACE inhibitor therapy alone in patients with IgA nephropathy: A randomized controlled trial. Am J Kidney Dis 53:26–32, 2009.Google Scholar

Manno, C, Torres, D D, Rossini, M, Pesce, F, Schena, F P: Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transplant 24:3694–3701, 2009.Google Scholar

Moriyama, T, Nakayama, K, Ochi, A, et al.: Comparison of inhibitors of renin–angiotensin–aldosterone system (RAS) and combination therapy of steroids plus RAS inhibitors for patients with advanced immunoglobulin A nephropathy and impaired renal function. Clin Exp Nephrol 16:231–237, 2012.Google Scholar

Moriyama, T, Amemiya, N, Ochi, A, et al.: Comparison of steroids and angiotensin receptor blockers for patients with advanced IgA nephropathy and impaired renal function. Am J Nephrol 34:233–240, 2011.Google Scholar

Tesar, V, Troyanov, S, Bellur, S, et al.: Corticosteroids in IgA Nephropathy: A Retrospective Analysis from the VALIGA Study. J Am Soc Nephrol 26:2248–2258, 2015.Google Scholar

Coppo, R: Is a legacy effect possible in IgA nephropathy? Nephrol Dial Transplant 28:1657–1662, 2013.Google Scholar

Wang, J, Juan, C, Huang, Q, Zeng, C, Liu, Z: Corticosteroid therapy in IgA nephropathy with minimal change-like lesions: A single-centre cohort study. Nephrol Dial Transplant 28:2339–2345, 2013.Google Scholar

Qin, J, Yang, Q, Tang, X, et al.: Clinicopathologic features and treatment response in nephrotic IgA nephropathy with minimal change disease. Clin Nephrol 79:37–44, 2013.Google Scholar

Xu, G, Tu, W, Jiang, D, Xu, C: Mycophenolate mofetil treatment for IgA nephropathy: A meta-analysis. Am J Nephrol 29:362–367, 2009.Google Scholar

Maes, B D, Oyen, R, Claes, K, et al.: Mycophenolate mofetil in IgA nephropathy: Results of a 3-year prospective placebo-controlled randomized study. Kidney Int 65:1842–1849, 2004.Google Scholar

Tang, S C, Tang, A W, Wong, S S, et al.: Long-term study of mycophenolate mofetil treatment in IgA nephropathy. Kidney Int 77:543–549, 2010.Google Scholar

Hogg, R J, Bay, R C, Jennette, J C, et al.: Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy. Am J Kidney Dis 66:783–791, 2015.Google Scholar

US National Library of Medicine: A prospective, multicenter, randomized controlled trial of mycophenolate mofetil (MMF) in patients with IgA nephropathy (IgAN). ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT00657059 (accessed December 30, 2014).Google Scholar

Pozzi, C, Andrulli, S, Pani, A, et al.: Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy. J Am Soc Nephrol 21:1783–1790, 2010.Google Scholar

Ballardie, F W, Roberts, I S. Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J Am Soc Nephrol 13:142–148, 2002.Google Scholar

Faul, C, Donnelly, M, Merscher-Gomez, S, et al.: The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 14:931–938, 2008.Google Scholar

Kim, Y C, Chin, H J, Koo, H S, Kim, S: Tacrolimus decreases albuminuria in patients with IgA nephropathy and normal blood pressure: A double-blind randomized controlled trial of efficacy of tacrolimus on IgA nephropathy. PLoS ONE 8:e71545, 2013.Google Scholar

Liu, L L, Wang, L N, Jiang, Y, et al.: Tonsillectomy for IgA nephropathy: A meta-analysis. Am J Kidney Dis. 65:80–87, 2015.Google Scholar

Canaud, G, Audard, V, Kofman, T, et al.: Recurrence from primary and secondary glomerulopathy after renal transplant. Transpl Int 25:812–824, 2012.Google Scholar

Kamal Aziz, A, Mousson, C, Berthoux, F, Ducloux, D, Chalopin, JM: Renal transplantation outcome in selected recipients with IgA nephropathy as native disease: A bicentric study. Ann Transplant 17:45–51, 2012.Google Scholar

Ortiz, F, Gelpi, R, Koskinen, P, et al.: IgA nephropathy recurs early in the graft when assessed by protocol biopsy. Nephrol Dial Transplant 27:2553–2558, 2012.Google Scholar

Sato, Y, Ishida, H, Shimizu, T, Tanabe, K: Evaluation of tonsillectomy before kidney transplantation in patients with IgA nephropathy. Transpl Immunol 30:12–17, 2014.Google Scholar

Hotta, K, Fukasawa, Y, Akimoto, M, et al.: Tonsillectomy ameliorates histological damage of recurrent immunoglobulin A nephropathy after kidney transplantation. Nephrology (Carlton) 18:808–812, 2013.Google Scholar

Heberden, W: De purpureis maculis. Chapter 78 in Commentaries on the History and Cure of Diseases. London, 1802.Google Scholar

Dr. Schönleins, J. L. allgemeine und specielle Pathologie und Therapie. Nach seinen Vorlesungen niedergeschrieben von einigen seiner Zuhörer und nicht autorisiert herausgegeben. Würzburg, Etlinger, 1832.Google Scholar

Henoch, E.: Über eine eigentümliche Form von Purpura. Berliner klinische Wochenschrift 11: 641, 1874.Google Scholar

Jennette, J C, Falk, R J, Bacon, P A, et al.: 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65:1–11, 2013.Google Scholar

Trapani, S, Micheli, A, Grisolia, F, et al.: Henoch Schonlein purpura in childhood: Epidemiological and clinical analysis of 150 cases over a 5-year period and review of literature. Semin Arthritis Rheum 35(3):143–153, 2005.Google Scholar

Gardner-Medwin, J M, Dolezalova, P, Cummins, C, Southwood, T R: Incidence of Henoch–Schonlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet 360(9341):1197–1202, 2002.Google Scholar

Haugeberg, G, Bie, R, Bendvold, A, et al.: Primary vasculitis in a Norwegian community hospital: A retrospective study. Clin Rheumatol 17(5):364–368, 1998.Google Scholar

Blanco, R, Martínez-Taboada, V M, Rodríguez-Valverde, V, García-Fuentes, M, González-Gay, M A: Henoch–Schönlein purpura in adulthood and childhood: Two different expressions of the same syndrome. Arthritis Rheum 40(5):859–864, 1997.Google Scholar

Pillebout, E, Thervet, E, Hill, G, et al.: Henoch–Schönlein Purpura in adults: Outcome and prognostic factors. J Am Soc Nephrol 13(5):1271–1278, 2002.Google Scholar

Saulsbury, F T: Epidemiology of Henoch–Schonlein purpura. Clev Clin J Med 69(Suppl 2):87–89, 2002.Google Scholar

Kellerman, P S: Henoch–Schonlein purpura in adults. Am J Kid Dis 48:1009–1016, 2006.Google Scholar

Mills, J A, Michel, B A, Bloch, D A, et al.: The American College of Rheumatology 1990 criteria for the classification of Henoch–Schonlein purpura. Arthritis Rheum 33:1114–1121, 1990.Google Scholar

Ozen, S, Pistorio, A, Iusan, S M, et al.: Paediatric Rheumatology International Trials Organisation (PRINTO): EULAR/PRINTO/ PRES criteria for Henoch–Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. Ann Rheum Dis 69:798–806, 2010.Google Scholar

Thrash, B, Patel, M, Shah, K R, Boland, C R, Menter, A: Cutaneous manifestations of gastrointestinal disease: Part II. J Am Acad Dermatol 68(2):211.e1–233; quiz 244–246, 2013.Google Scholar

Chan, K H, Tang, W Y, Lo, K K: Bullous lesions in Henoch–Schonlein purpura. Pediatr Dermatol 24(3):325–326, 2007.Google Scholar

Shiohama, T, Kitazawa, K, Omura, K, et al.: Intussusception and spontaneous ileal perforation in Henoch–Schönlein purpura. Pediatr Int 50:709–710, 2008.Google Scholar

Bilici, S, Akgun, C, Melek, M, et al.: Acute appendicitis in two children with Henoch–Schönlein purpura. Paediatr Int Child Health 32(4):244–245, 2012.Google Scholar

Ha, T S, Lee, J S: Scrotal involvement in childhood Henoch–Schonlein purpura. Acta Paediatr 96(4):552–555, 2007.Google Scholar

Ozkaya, O, Bek, K, Alaca, N, et al.: Cerebral vasculitis in a child with Henoch–Schonlein purpura and familial Mediterranean fever. Clin Rheumatol 26(10):1729–1732, 2007.Google Scholar

Takeuchi, S, Soma, Y, Kawakami, T: IgM in lesional skin of adults with Henoch–Schönlein purpura is an indication of renal involvement. J Am Acad Dermatol 63(6):1026–1029, 2010.Google Scholar

Davin, J C, Coppo, R: Henoch–Schönlein purpura nephritis in children. Nat Rev Nephrol 10:563–573, 2014.Google Scholar

Heaton, J M, Turner, D R, Cameron, J S: Localization of glomerular “deposits” in Henoch–Schonlein nephritis. Histopathology 1:93–104, 1977.Google Scholar

Szeto, C C, Choi, P C, To, K F, et al.: Grading of acute and chronic renal lesions in Henoch–Schonlein purpura. Mod Pathol 14:635–640, 2001.Google Scholar

Zollinger, H U, Mihatsch, M J, Gaboardi, F, et al.: Schonlein–Henoch glomerulonephritis. Characteristic ultrastructural changes in the glomerular basement membrane and localisation of osmiophilic deposits. Virchows Archiv A, Pathol Anat Histol 388:155–165, 1980.Google Scholar

Ozaltin, F, Bakkaloglu, A, Ozen, S, et al.: The significance of IgA class of antineutrophil cytoplasmic antibodies (ANCA) in childhood Henoch–Schonlein purpura. Clin Rheumatol 23:426–429, 2004.Google Scholar

Coppo, R, Cirina, P, Amore, A, et al.: Properties of circulating IgA molecules in Henoch–Schonlein purpura nephritis with focus on neutrophil cytoplasmic antigen IgA binding (IgA-ANCA): New insight into a debated issue. Italian Group of Renal Immunopathology Collaborative Study on Henoch–Schonlein purpura in adults and in children. Nephrol Dial Transplant 12:2269–2276, 1997.Google Scholar

Mookerjee, B K, Maddison, P J, Reichlin, M: Case report: Mesangial IgA–IgG deposition in mixed cryoglobulinemia. Am J Med Sci 276:221–225, 1978.Google Scholar

Rollino, C, Dieny, A, Le Marc’hadour, F, et al.: Double monoclonal cryoglobulinemia, glomerulonephritis and lymphoma. Nephron 62:459–464, 1992.Google Scholar

Yang, Y H, Huang, M T, Lin, S C, et al.: Increased transforming growth factor-beta (TGF-beta)-secreting T cells and IgA anti-cardiolipin antibody levels during acute stage of childhood Henoch–Schonlein purpura. Clin Exp Immunol 122:285–290, 2000.Google Scholar

Kawakami, T, Watabe, H, Mizoguchi, M, Soma, Y: Elevated serum IgA anticardiolipin antibody levels in adult Henoch–Schonlein purpura. Brit J Dermatol 155:983–987, 2006.Google Scholar

Rigante, D, Castellazzi, L, Bosco, A, Esposito, S: Is there a crossroad between infections, genetics, and Henoch–Schönlein purpura? Autoimmun Rev 12(10):1016–1021, 2013.Google Scholar

Masuda, M, Nakanishi, K, Yoshizawa, N, Iijima, K, Yoshikawa, N: Group A streptococcal antigen in the glomeruli of children with Henoch–Schonlein nephritis. Am J Kidney Dis 41:366–370, 2003.Google Scholar

Ogura, Y, Suzuki, S, Shirakawa, T, et al.: Haemophilus parainfluenzae antigen and antibody in children with IgA nephropathy and Henoch–Schönlein nephritis. Am J Kidney Dis 36:47–52, 2000.Google Scholar

Zurada, J M, Ward, K M, Grossman, M E: Henoch–Schonlein purpura associated with malignancy in adults. J Am Acad Dermatol 55(5 Suppl):65–70, 2006.Google Scholar

Gonzalez-Gay, M A, Calvino, M C, Vazquez-Lopez, M E, et al. Implications of upper respiratory tract infections and drugs in the clinical spectrum of Henoch–Schonlein purpura in children. Clin Exp Rheumatol 22:781–784, 2004.Google Scholar

Davin, J C, Ten Berge, I J, Weening, J J: What is the difference between IgA nephropathy and Henoch–Schönlein purpura nephritis? Kidney Int 59:823–834, 2001.Google Scholar

Meadow, S R, Scott, D G: Berger disease: Henoch–Schönlein without the rash. J Pediatr 106:27–32, 1985.Google Scholar

Allen, A C, Willis, F R, Beattie, T J, Feehally, J: Abnormal IgA glycosylation in Henoch–Schönlein purpura restricted to patients with clinical nephritis. Nephrol Dial Transplant 13:930–934, 1998.Google Scholar

Davin, J C, Pierard, G, Dechenne, C, et al.: Possible pathogenic role of IgE in Henoch–Schönlein purpura. Pediatr Nephrol 8:169–171, 1994.Google Scholar

Kawasaki, Y, Hosoya, M, Suzuki, H: Possible pathologenic role of interleukin-5 and eosino cationic protein in Henoch–Schönlein purpura nephritis. Pediatr Int 47:512–517, 2005.Google Scholar

Namgoong, M K, Lim, B K, Kim, J S: Eosinophil cationic protein in Henoch–Schönlein purpura and in IgA nephropathy. Pediatr Nephrol 11:703–706, 1997.Google Scholar

Davin, J-C.: Henoch–Schonlein purpura nephritis: Pathophysiology, treatment, and future strategy. Clin J Am Soc Nephrol 6:679–689, 2011.Google Scholar

Lin, Q, Min, Y, Li, Y, et al.: Henoch–Schönlein purpura with hypocomplementemia. Pediatr Nephrol 27:801–806, 2012.Google Scholar

Couser, W G: Basic and translational conceptys of immune-mediated glomerular diseases. J Am Soc Nephrol 23:381–399, 2012.Google Scholar

Jennette, J C: Rapidly progressive crescentic glomerulonephritis. Kidney Int 63:1164–1177, 2003.Google Scholar

Hisano, S, Matsushita, M, Fujita, T, Iwasaki, H: Activation of the lectin complement pathway in Henoch–Schönlein purpura nephritis. Am J Kidney Dis 45:295–302, 2005.Google Scholar

Roos, A, Rastaldi, M P, Calvaresi, N, et al.: Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. J Am Soc Nephrol 17:1724–1734, 2006.Google Scholar

Espinosa, M, Ortega, R, Gomez-Carrasco, J M, et al.: Mesangial C4d deposition: A new prognostic factor in IgA nephropathy. Nephrol Dial Transplant 24:886–891, 2009.Google Scholar

Levy, M: Familial cases of Berger’s disease and anaphylactoid purpura. Kidney Int 60:1611–1612, 2001.Google Scholar

Julian, B A, Quiggins, P A, Thompson, J S, et al.: Familial IgA nephropathy. Evidence of an inherited mechanism of disease. N Engl J Med 312:202–208, 1985.Google Scholar

Meadow, S R, Scott, D G: Berger disease: Henoch–Schönlein syndrome without the rash. J Pediatr 106:27–32, 1985.Google Scholar

Kiryluk, K, Moldoveanu, Z, Sanders, J T, Eison, TM: Aberrant glycosylation of IgA1 is inherited in both pediatric IgA nephropathy and Henoch–Schönlein purpura nephritis. Kidney Int 80:79–87, 2011.Google Scholar

He, X, Yu, C, Zhao, P, et al.: The genetics of Henoch–Schönlein purpura: A systematic review and meta-analysis. Rheum Int 33:1387–1395, 2013.Google Scholar

Altug, U, Ensari, C, Sayin, D B, Ensari, A: MEFV gene mutations in Henoch–Schönlein purpura. Int J Rheum Dis 16:347–351, 2013.Google Scholar

López-Mejías, R, Genre, F, Pérez, B S, et al.: Association of HLA–DRB1*01 with IgA vasculitis (Henoch–Schönlein). Arthritis Rheum 67:823–827, 2015.Google Scholar

Yoshikawa, N, White, R H, Cameron, A H: Prognostic significance of the glomerular changes in Henoch–Schoenlein nephritis. Clin Nephrol 16:223–229, 1981.Google Scholar

Meadow, S R, Glasgow, E F, White, R H, et al.: Schonlein–Henoch nephritis. Q J Med 41:241–258, 1972.Google Scholar

Saulsbury, F T: Clinical update: Henoch–Schönlein purpura. Lancet 369:976–978, 2007.Google Scholar

Waldo, F B: Is Henoch–Schönlein purpura the systemic form of IgA nephropathy? Am J Kidney Dis 12:373–377, 1988.Google Scholar

Nakamoto, Y, Asano, Y, Dohi, K, et al.: Primary IgA glomerulonephritis and Schönlein–Henoch purpura nephritis: Clinicopathological and immunohistological characteristics. Q J Med 47:495–516, 1978.Google Scholar

Calvino, M C, Llorca, J, Garcia-Porrua, C, et al.: Henoch–Schonlein purpura in children from northwestern Spain: A 20-year epidemiologic and clinical study. Medicine (Baltimore) 80:279–290, 2001.Google Scholar

Narchi, H: Risk of long term renal impairment and duration of follow up recommended for Henoch–Schonlein purpura with normal or minimal urinary findings: A systematic review. Arch Dis Child 90:916–920, 2005.Google Scholar

Saulsbury, F T: Henoch–Schonlein purpura in children – Report of 100 patients and review of the literature. Medicine 78:395–409, 1999.Google Scholar

Goldstein, A R, White, R H R, Akuse, R, Chantler, C: Long-term follow-up of childhood Henoch–Schonlein nephritis. Lancet 339:280–282, 1992.Google Scholar

Scharer, K, Krmar, R, Querfeld, U, et al.: Clinical outcome of Schonlein–Henoch purpura nephritis in children. Pediatr Nephrol 13:816–823, 1999.Google Scholar

Ronkainen, J, Nuutinen, M, Koskimies, O: The adult kidney 24 years after childhood Henoch–Schonlein purpura: A retrospective cohort study. Lancet 360:666–670, 2002.Google Scholar

Edstrom-Halling, S, Soderberg, M P, Berg, U B: Predictors of outcome in Henoch–Schonlein nephritis. Pediatr Nephrol 25:1101–1108, 2010.Google Scholar

Wakaki, H, Ishikura, K, Hataya, H, et al.: Henoch–Schönlein purpura nephritis with nephrotic state in children: Predictors of poor outcomes. Pediatr Nephrol 26:921–925, 2011.Google Scholar

Xia, Y, Mao, J, Chen, Y, et al.: Clinical outcomes in children with Henoch–Schönlein purpura nephritis grade IIIa or IIIb. Pediatr Nephrol 26:1083–1088, 2011.Google Scholar

Deng, F, Lu, L, Zhang, Q, et al.: Henoch–Schönlein purpura in childhood: Treatment and prognosis. Analysis of 425 cases over a 5-year period. Clin Rheumatol 29:369–374, 2010.Google Scholar

Bunchman, T E, Mauer, S M, Sibley, R K, Vernier, R L: Anaphylactoid purpura: Characteristics of 16 patients who progressed to renal failure. Pediatr Nephrol 2:393–397, 1988.Google Scholar

Niaudet, P, Murcia, I, Beaufils, H, Broyer, M, Habib, R: Primary IgA nephropathies in children: Prognosis and treatment. Adv Nephrol Necker Hospital 22:121–140, 1993.Google Scholar

Nussinovitch, N, Elishkevitz, K, Volovitz, B, Nussinovitch, M: Hypertension as a late sequela of Henoch–Schonlein purpura. Clin Pediatr 44:543–547, 2005.Google Scholar

Kaku, Y, Nohara, K, Honda, S: Renal involvement in Henoch–Schonlein purpura: A multivariate analysis of prognostic factors. Kidney Int 53:1755–1759, 1998.Google Scholar

Sano, H, Izumida, M, Shimizu, H, Ogawa, Y: Risk factors of renal involvement and significant proteinuria in Henoch–Schonlein purpura. Eur J Ped 161:196–201, 2002.Google Scholar

Poterucha, T J, Wetter, D A, Gibson, L E, Camilleri, M J, Lohse, C M: Histopathology and correlates of systemic disease in adult Henoch–Schonlein purpura: A retrospective study of microscopic and clinical findings in 68 patients at Mayo Clinic. J Am Acad Dermatol 68:420e3–424e3, 2013.Google Scholar

Guo, Y N, Wang, Z, Lu, J: The relationship between children kidney diseases and adult ESRD – An epidemiological investigation of 700 cases. Ren Fail 35:1353–1357, 2013.Google Scholar

Kellerman, P S: Henoch–Schonlein purpura in adults. Am J Kidney Dis 48:1009–1016, 2006.Google Scholar

Coppo, R, Andrulli, S, Amore, A, et al.: Predictors of outcome in Henoch–Schonlein nephritis in children and adults. Am J Kidney Dis 47:993–1003, 2006.Google Scholar

Shrestha, S, Sumingan, N, Tan, J, et al.: Henoch Schonlein purpura with nephritis in adults: Adverse prognostic indicators in a UK population. Quart J Med 99:253–265, 2006.Google Scholar

Coppo, R, Mazzucco, G, Cagnoli, L, Lupo, A, Schena, F P: Long-term prognosis of Henoch–Schonlein nephritis in adults and children. Italian Group of Renal Immunopathology Collaborative Study on Henoch Schonlein purpura. Nephrol Dial Transplant 12:2277–2283, 1997.Google Scholar

Zaffanello, M, Fanos, V: Treatment-based literature of Henoch–Schonlein purpura nephritis in childhood. Pediatr Nephrol 24:1901–1911, 2009.Google Scholar

Ronkainen, J, Koskimies, O, Ala-Houhala, M, et al.: Early prednisone therapy in Henoch–Schonlein purpura: A randomized, double-blind, placebocontrolled trial. J Pediatr 149:241–247, 2006.Google Scholar

Jauhola, O, Ronkainen, J, Koskimies, O, et al.: Outcome of Henoch–Schönlein purpura 8 years after treatment with a placebo or prednisone at disease onset. Pediatr Nephrol 27:933–939, 2012.Google Scholar

Dudley, J, Smith, G, Llewelyn-Edwards, A, et al.: Randomised, double-blind, placebo-controlled trial to determine whether steroids reduce the incidence and severity of nephropathy in Henoch–Schonlein Purpura (HSP). Arch Dis Child 98:756–763, 2013.Google Scholar

Niaudet, P, Habib, R: Methylprednisolone pulse therapy in the treatment of severe forms of SchonleiniHenoch purpura nephritis. Pediatr Nephrol 12:238–243, 1998.Google Scholar

Tarshish, P, Bernstein, J, Edelmann, C M Jr: Henoch–Schonlein purpura nephritis: Course of disease and efficacy of cyclophosphamide. Pediatr Nephrol 19:51–56, 2004.Google Scholar

Kawasaki, Y, Suzuki, J, Suzuki, H: Efficacy of methylprednisolone and urokinase pulse therapy combined with or without cyclophosphamide in severe Henoch–Schoenlein nephritis: A clinical and histopathological study. Nephrol Dial Transplant 19:858–864, 2004.Google Scholar

Pillebout, E, Alberti, C, Guillevin, L, et al.: Addition of cyclophosphamide to steroids provides no benefit compared with steroids alone in treating adult patients with severe Henoch Schonlein Purpura. Kidney Int 78:495–502, 2010.Google Scholar

Park, J M, Won, S C, Shin, J I, Yim, H, Pai, K S: Cyclosporin A therapy for Henoch–Schönlein nephritis with nephrotic-range proteinuria. Pediatr Nephrol 26:411–417, 2011.Google Scholar

Kalliakmani, P, Benou, E, Goumenos, D S: Cyclosporin A in adult patients with Henoch–Schönlein purpura nephritis and nephrotic syndrome; 5 case reports. Clin Nephrol 75:380–383, 2011.Google Scholar

Du, Y, Hou, L, Zhao, C, Han, M, Wu, Y: Treatment of children with Henoch–Schönlein purpura nephritis with mycophenolate mofetil. Pediatr Nephrol 27:765–771, 2012.Google Scholar

Ren, P, Han, F, Chen, L, et al.: The combination of mycophenolate mofetil with corticosteroids induces remission of Henoch–Schönlein purpura nephritis. Am J Nephrol 36:271–277, 2012.Google Scholar

Han, S S, Sun, H K, Lee, J P, et al.: Outcome of renal allograft in patients with Henoch–Schönlein nephritis: Single-center experience and systematic review. Transplantation 89:721–726, 2010.Google Scholar

Alport, A C: Heriditary familial congenital haemorrhagic nephritis. Br Med J 1:504–506, 1927.Google Scholar

Williamson, D A: Alport’s syndrome of hereditary nephritis with deafness. Lancet 2:1321–1323, 1961Google Scholar

Barker, D F, Hostikka, S L, Zhou, J, et al.: Identification of mutations in the COL4A5 collagen gene in Alport syndrome. Science 248:1224–1227, 1990.Google Scholar

Kashtan, C E: Familial hematuria. Pediatr Nephrol 24:1951–1958, 2009.Google Scholar

Kruegel, J, Rubel, D, Gross, O: Alport syndrome – Insights from basic and clinical research. Nat Rev Nephrol 9:170–178, 2013.Google Scholar

Savige, J, Sheth, S, Leys, A, et al.: Ocular features in Alport syndrome: Pathogenesis and clinical significance. Clin J Am Soc Nephrol 10:703–709, 2015.Google Scholar

Ahmed, F, Kamae, K K, Jones, D J, et al.: Temporal macular thinning associated with X-linked Alport syndrome. JAMA Ophthalmol 9:1–6, 2013.Google Scholar

Citirik, M, Batman, C, Men, G, Tuncel, M, Zilelioglu, O: Electron microscopic examination of the anterior lens capsule in a case of Alport’s syndrome. Clin Exp Optom 90:367–370, 2007.Google Scholar

Miner, J H: Alport syndrome with diffuse leiomyomatosis. When and when not? Am J Pathol 154:1633–1635, 1999.Google Scholar

Thielen, B K, Barker, D F, Nelson, R D, et al.: Deletion mapping in Alport syndrome and Alport syndrome-diffuse leiomyomatosis reveals potential mechanisms of visceral smooth muscle overgrowth. Hum Mutat 22:419, 2003.Google Scholar

Dagher, H, Buzza, M, Colville, D, et al.: A comparison of the clinical, histopathologic, and ultrastructural phenotypes in carriers of X-linked and autosomal recessive Alport’s syndrome. Am J Kidney Dis 38:1217–1228, 2001.Google Scholar

Mazzucco, G, Barsotti, P, Muda, A O, et al.: Ultrastructural and immunohistochemical findings in Alport’s syndrome: a study of 108 patients from 97 Italian families with particular emphasis on COL4A5 gene mutation correlations. J Am Soc Nephrol 9:1023–1031, 1998.Google Scholar

Gong, W, Liu, Z H, Chen, H P, et al.: Spectrum of clinical features and type IV collagen alpha-chain distribution in Chinese patients with Alport syndrome. Nephrol Dial Transplant 21:3146–3154, 2006.Google Scholar

Rizzoni, G, Massella, L: Differential diagnosis between X-linked Alport syndrome and thin basement membrane nephropathy. Kidney Int 66:1289–1290, 2004.Google Scholar

van der Loop, F T, Heidet, L, Timmer, E D, et al.: Autosomal dominant Alport syndrome caused by a COL4A3 splice site mutation. Kidney Int 58:1870–1875, 2000.Google Scholar

Spear, G S, Slusser, R J: Alport’s syndrome. Emphasizing electron microscopic studies of the glomerulus. Am J Pathol 69:213–224, 1972.Google Scholar

Liapis, H, Gokden, N, Hmiel, P, Miner, J H: Histopathology, ultrastructure, and clinical phenotypes in thin glomerular basement membrane disease variants. Hum Pathol 33:836–845, 2002.Google Scholar

Nadasdy, T, Abdi, R, Pitha, Jan P, Slakey, D, Racusen, L: Diffuse glomerular basement membrane lamellation in renal allografts from pediatric donors to adult recipients. Am J Surg Pathol 23:437–442, 1999.CrossRef Google Scholar PubMed

Meleg-Smith, S: Alport disease: A review of the diagnostic difficulties. Ultrastruct Pathol 25:193–200, 2001.Google Scholar

Mazzucco, G, De Marchi, M, Monga, G: Renal biopsy interpretation in Alport Syndrome. Semin Diag Pathol 19:133–145, 2002.Google Scholar

Jais, J P, Knebelmann, B, Giatras, I, et al.: X-linked Alport syndrome: Natural history and genotype–phenotype correlations in girls and women belonging to 195 families: a “European Community Alport Syndrome Concerted Action” study. J Am Soc Nephrol 14:2603–2610, 2003.Google Scholar

Cangiotti, A M, Sessa, A, Meroni, M, et al.: Evolution of glomerular basement membrane lesions in a male patient with Alport syndrome: Ultrastructural and morphometric study. Nephrol Dial Transplant 11:1829–1834, 1996.Google Scholar

Hudson, B G, Tryggvason, K, Sundaramoorthy, M, Neilson, E G: Alport’s syndrome, Goodpasture’s syndrome, and type IV collagen. N Engl J Med 348:2543–2556, 2003.Google Scholar

Hudson, B G: The molecular basis of Goodpasture and Alport syndromes: Beacons for the discovery of the collagen IV family. J Am Soc Nephrol 15:2514–2527, 2004.Google Scholar

Heidet, L, Cai, Y, Guicharnaud, L, Antignac, C, Gubler, M C: Glomerular expression of type IV collagen chains in normal and X-linked Alport syndrome kidneys. Am J Pathol 156:1901–1910, 2000.Google Scholar

Parkin, J D, San Antonio, J D, Pedchenko, V, et al.: Mapping structural landmarks, ligand binding sites, and missense mutations to the collagen IV heterotrimers predicts major functional domains, novel interactions, and variation in phenotypes in inherited diseases affecting basement membranes. Hum Mutat 32:127–143, 2011.Google Scholar

Kabosova, A, Azar, D T, Bannikov, G A, et al.: Compositional differences between infant and adult human corneal basement membranes. Invest Ophthalmol Vis Sci 48:4989–4999, 2007.Google Scholar

Savige, J, Liu, J, DeBuc, D C, et al.: Retinal basement membrane abnormalities and the retinopathy of Alport syndrome. Invest Ophthalmol Vis Sci 51:1621–1627, 2010.Google Scholar

Hertz, J M, Thomassen, M, Storey, H, Flinter, F: Clinical utility gene card for: Alport syndrome. Eur J Hum Genet 20:20, 2012.Google Scholar

Kalluri, R, Shield, C F, Todd, P: Isoform switching of type IV collagen is developmentally arrested in X- linked Alport syndrome leading to increased susceptibility of renal basement membranes to endoproteolysis. J Clin Invest 99:2470–2478, 1997.Google Scholar

Malone, A F, Phelan, P J, Hall, G, et al.: Rare hereditary COL4A3/COL4A4 variants may be mistaken for familial focal segmental glomerulosclerosis Kidney Int 86:1253–1259, 2014.Google Scholar

Xie, J, Wu, X, Ren, H, et al.: COL4A3 mutations cause focal segmental glomerulosclerosis. J Mol Cell Biol 6:498–505, 2014.Google Scholar

Savige, J, Gregory, M, Gross, O, et al.: Expert guidelines for the management of Alport syndrome and thin basement membrane nephropathy. J Am Soc Nephrol 24:364–375, 2013.Google Scholar

Webb, N J, Shahinfar, S, Wells, T G, et al.: Losartan and enalapril are comparable in reducing proteinuria in children with Alport syndrome. Pediatr Nephrol 28:737–743, 2013.Google Scholar

Charbit, M, Gubler, M C, Dechaux, M, et al.: Cyclosporin therapy in patients with Alport syndrome. Pediatr Nephrol 22:57–63, 2007.Google Scholar

Olaru, F, Luo, W, Wang, X P, et al.: Quaternary epitopes of a345(IV) collagen initiate Alport post-transplant anti-GBM nephritis. J Am Soc Nephrol 24:889–895, 2013.Google Scholar

Wang, X P, Fogo, A B, Colon, S, et al.: Distinct epitopes for anti-glomerular basement membrane alport alloantibodies and Goodpasture autoantibodies within the noncollagenous domain of alpha3(IV) collagen: A Janus-faced antigen. J Am Soc Nephrol 16:3563–3571, 2005.Google Scholar

Borza, D B: Autoepitopes and alloepitopes of type IV collagen: Role in the molecular pathogenesis of anti-GBM antibody glomerulonephritis. Nephron Exp Nephrol 106:e37–43, 2007.Google Scholar

Kashtan, C E: Alport syndrome and thin glomerular basement membrane disease. J Am Soc Nephrol 9:1736–1750, 1998.Google Scholar

Armstead, S, Hellmark, T, Wieslander, J, et al.: A case of Alport syndrome with post-transplant anti-glomerular basement membrane disease despite negative anti-glomerular basement membrane antibodies by ELISA treated with plasmapheresis and intravenous immunoglobulin. Case Rep Transplant 2013:164916, 2013.Google Scholar

Baehr, G.: Benign and curable form of hemorrhagic nephritis. J Am Med Assoc 86:1001–1004, 1926.Google Scholar

McConville, J M, McAdams, A J: Familial and nonfamilal benign hematuria. J Pediatr 69:207–214, 1996.Google Scholar

Rogers, P W, Kurtzman, N A, Bunn, S M, White, M G: Famalial benign essential hematuria. Arch Intern Med 131:237–262, 1973.Google Scholar

Wang, Y Y, Rana, K, Tonna, S, et al.: COL4A3 mutations and their clinical consequences in thin basement membrane nephropathy (TBMN). Kidney Int 65:786–790, 2004.Google Scholar

Lemmink, H H, Nillesen, W N, Mochizuki, T, et al.: Benign familial hematuria due to mutation of the type IV collagen alpha4 gene. J Clin Invest 98:1114–1118, 1996.Google Scholar

Tryggvason, K, Patrakka, J: Thin basement membrane nephropathy. J Am Soc Nephrol 17:813–822, 2006.Google Scholar

Haas, M: Thin glomerular basement membrane nephropathy: Incidence in 3471 consecutive renal biopsies examined by electron microscopy. Arch Pathol Lab Med 130:699–706, 2006.Google Scholar

Savige, J, Rana, K, Tonna, S, et al.: Thin basement membrane nephropathy. Kidney Int 64:1169–1178, 2003.Google Scholar

van Paassen, P, van Breda Vriesman, P J, van Rie, H, Tervaert, J W: Signs and symptoms of thin basement membrane nephropathy: A prospective regional study on primary glomerular disease – The Limburg Renal Registry. Kidney Int 66:909–913, 2004.Google Scholar

Voskarides, K, Damianou, L, Neocleous, V, et al.: COL4A3/COL4A4 mutations producing focal segmental glomerulosclerosis and renal failure in thin basement membrane nephropathy. J Am Soc Nephrol 18:3004–3016, 2007.Google Scholar

Norby, S M, Cosio, F G: Thin basement membrane nephropathy associated with other glomerular diseases. Semin Nephrol 25:176–179, 2005.Google Scholar

Foster, K, Markowitz, G S, D’Agati, V D: Pathology of thin basement membrane nephropathy. Semin Nephrol 25:149–158, 2005.Google Scholar

Churg, J, Bernstein, J, Glassock, R J (eds): Renal Disease: Classification and Atlas of Glomerular Diseases (2nd ed). (New York, Igaku-Shoin, 1995).Google Scholar

Ivanyi, B, Pap, R, Ondrik, Z: Thin basement membrane nephropathy: Diffuse and segmental types. Arch Pathol Lab Med 130:1533–1537, 2006.Google Scholar

Rana, K, Wang, Y Y, Buzza, M, et al.: The genetics of thin basement membrane nephropathy. Semin Nephrol 25:163–170, 2005.Google Scholar

Szeto, C C, Mac-Moune Lai, F, Kwan, B C, et al.: The width of the basement membrane does not influence clinical presentation or outcome of thin glomerular basement membrane disease with persistent hematuria. Kidney Int 78:1041–1046, 2010.Google Scholar

Tonna, S, Wang, Y Y, MacGregor, D, et al.: The risks of thin basement membrane nephropathy. Semin Nephrol 25:171–175, 2005.Google Scholar

Temme, J, Peters, F, Lange, K, et al.: Incidence of renal failure and nephroprotection by RAAS inhibition in heterozygous carriers of X-chromosomal and autosomal recessive Alport mutations. Kidney Int 81:779–783, 2012.Google Scholar

Ierino, F L, Kanellis, J: Thin basement membrane nephropathy and renal transplantation. Semin Nephrol 25:184–187, 2005.Google Scholar

Sakai, K, Muramatsu, M, Ogiwara, H, et al.: Living related kidney transplantation in a patient with autosomal-recessive Alport syndrome. Clin Transplant 17(Suppl 10):4–8, 2003.Google Scholar

Little, P J, Sloper, J S, de Wardener, HE: A syndrome of loin pain and haematuria associated with disease of peripheral renal arteries. Quart J Med 36:253–259, 1967.Google Scholar

Spetie, D N, Nadasdy, T, Nadasdy, G, et al.: Proposed pathogenesis of idiopathic loin pain-hematuria syndrome. Am J Kidney Dis 47:419–427, 2006.Google Scholar

Dube, G K, Hamilton, S E, Ratner, L E, Nasr, S H, Radhakrishnan, J: Loin pain hematuria syndrome. Kidney Int 70:2152–2155, 2006.Google Scholar

Taba Taba Vakili, S, Alam, T, Sollinger, H: Loin pain hematuria syndrome. Am J Kidney Dis 64:460–472, 2014.Google Scholar

Lall, R, Mailis, A, Rapoport, A: Hematuria-loin pain syndrome: Its existence as a discrete clinicopathological entity cannot be supported. Clin J Pain 13:171–177, 1997.Google Scholar

Bultitude, M, Young, J, Bultitude, M, Allan, J. Loin pain haematuria syndrome: Distress resolved by pain relief. Pain 76(1–2):209, 1998.Google Scholar

Gambaro, G, Fulignati, P, Spinelli, A, Rovella, V, Di Daniele, N: Percutaneous renal sympathetic nerve ablation for loin pain haematuria syndrome. Nephrol Dial Transplant 28:2393–2395, 2013.Google Scholar

Diwakar, R, Andrews, P A: Renal transplantation in a patient with loin pain hematuria syndrome. Clin Nephrol 66:144–146, 2006.Google Scholar

Book contents

Chapter 5 - Glomerular Diseases Associated Primarily with Asymptomatic or Gross Hematuria

Access options

References

Book contents

Chapter 5 - Glomerular Diseases Associated Primarily with Asymptomatic or Gross Hematuria

Access options

References

Save book to Kindle

Save book to Dropbox

Save book to Google Drive